Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01405651 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

A Phase 1 study, sponsored by Ono Pharma USA.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01405651: Completed Phase 1 study, sponsored by Ono Pharma USA.

NCT01405651 is a Phase 1 study that has completed, run by Ono Pharma USA. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01405651, a Phase 1 study, has completed, sponsored by Ono Pharma USA.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of ONO-6950 across ascending multiple doses in healthy adult male and female subjects. The secondary objectives are to characterize the PK and pharmacodynamic (PD) profiles of ONO-6950 by measuring plasma concentrations of ONO-6950 and pulmonary function.

Interventions

  • DRUG ONO-6950

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2011-07
Phase Phase 1
Ono Pharma USA

17 total trials

What the finished NCT01405651 record still lists

NCT01405651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).

The record links to 0 conditions, and to 1 intervention - of which ONO-6950 is the first listed.

NCT01405651 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01405651 about?

NCT01405651 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects". The primary objective of this study is to evaluate the safety and tolerability of ONO-6950 across ascending multiple doses in healthy adult male and female subjects. The secondary objectives are to characterize the PK and pharmacodynamic (PD) profiles of ONO-6950 by measuring plasma concentrations o...

What is the current status of trial NCT01405651?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-07.

What interventions are being tested in trial NCT01405651?

The interventions under investigation include: ONO-6950 (DRUG).

Who is sponsoring clinical trial NCT01405651?

This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01405651's enrollment target sits among peer trials

24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01405651, the US trial registry maintained by the National Library of Medicine. NCT01405651 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.